TScan Therapeutics (NASDAQ:TCRX) Major Shareholder Lynx1 Capital Management Lp Buys 80,069 Shares of Stock

TScan Therapeutics, Inc. (NASDAQ:TCRX) major shareholder Lynx1 Capital Management Lp bought 80,069 shares of TScan Therapeutics stock in a transaction on Friday, December 19th. The shares were bought at an average cost of $0.90 per share, with a total value of $72,062.10. Following the acquisition, the insider directly owned 7,937,416 shares in the company, valued at approximately $7,143,674.40. This represents a 1.02% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Lynx1 Capital Management Lp also recently made the following trade(s):

• On Tuesday, December 23rd, Lynx1 Capital Management Lp bought 6,232 shares of TScan Therapeutics stock. The stock was acquired at an average price of $0.90 per share, for a total transaction of $5,608.80.
• On Monday, December 22nd, Lynx1 Capital Management Lp acquired 75,500 shares of TScan Therapeutics stock. The stock was bought at an average price of $0.90 per share, for a total transaction of $67,950.00.

TScan Therapeutics Price Performance

Shares of NASDAQ:TCRX opened at $0.91 on Wednesday. The company’s fifty day moving average price is $1.35 and its 200-day moving average price is $1.62. The company has a debt-to-equity ratio of 0.23, a current ratio of 6.44 and a quick ratio of 6.44. The firm has a market capitalization of $51.68 million, a price-to-earnings ratio of -0.81 and a beta of 1.03. TScan Therapeutics, Inc. has a one year low of $0.88 and a one year high of $3.43.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.07. The company had revenue of $2.51 million for the quarter, compared to analysts’ expectations of $1.98 million. TScan Therapeutics had a negative return on equity of 73.33% and a negative net margin of 1,692.96%. On average, equities research analysts anticipate that TScan Therapeutics, Inc. will post -1.12 earnings per share for the current fiscal year.

Analyst Ratings Changes

TCRX has been the subject of a number of research analyst reports. HC Wainwright dropped their price target on TScan Therapeutics from $10.00 to $7.00 and set a “buy” rating for the company in a research note on Thursday, November 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of TScan Therapeutics in a research report on Wednesday, October 8th. Morgan Stanley lowered shares of TScan Therapeutics from an “overweight” rating to an “equal weight” rating in a research note on Friday, November 14th. Needham & Company LLC reduced their price target on shares of TScan Therapeutics from $9.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, November 4th. Finally, BTIG Research lowered shares of TScan Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday, November 4th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, TScan Therapeutics has a consensus rating of “Hold” and an average target price of $6.60.

Institutional Trading of TScan Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of TCRX. Catalyst Funds Management Pty Ltd purchased a new stake in shares of TScan Therapeutics during the second quarter valued at $26,000. Vanguard Personalized Indexing Management LLC purchased a new stake in shares of TScan Therapeutics during the 2nd quarter valued at about $29,000. Quadrature Capital Ltd bought a new stake in shares of TScan Therapeutics in the second quarter worth approximately $33,000. Boothbay Fund Management LLC raised its holdings in shares of TScan Therapeutics by 50.0% during the second quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company’s stock valued at $35,000 after purchasing an additional 8,121 shares during the last quarter. Finally, Hsbc Holdings PLC purchased a new position in shares of TScan Therapeutics during the first quarter valued at approximately $49,000. 82.83% of the stock is currently owned by institutional investors.

About TScan Therapeutics

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.